

This is the peer reviewed version of the following article:

Negative Epistasis and Evolvability in TEM-1 β -Lactamase—The Thin Line between an Enzyme's Conformational Freedom and Disorder / Dellus Gur, Eynat; Elias, Mikael; Tawfik, Dan S; Caselli, Emilia; Prati, Fabio; Salverda, Merijn L. M; De Visser, J. Arjan G. M; Fraser, James S.. - In: JOURNAL OF MOLECULAR BIOLOGY. - ISSN 1089-8638. - STAMPA. - 427:14(2015), pp. 2396-2409. [10.1016/j.jmb.2015.05.011]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

04/05/2024 11:29

Accepted Manuscript

Negative epistasis and evolvability in TEM-1 β -lactamase – The thin line between an enzyme's conformational freedom and disorder

Eynat Dellus-Gur, Mikael Elias, Emilia Caselli, Fabio Prati, Merijn L.M. Salverda, J. Arjan G.M. de Visser, James S. Fraser, Dan S. Tawfik

PII: S0022-2836(15)00295-8
DOI: doi: [10.1016/j.jmb.2015.05.011](https://doi.org/10.1016/j.jmb.2015.05.011)
Reference: YJMBI 64756

To appear in: *Journal of Molecular Biology*

Received date: 9 January 2015
Revised date: 8 May 2015
Accepted date: 12 May 2015



Please cite this article as: Dellus-Gur, E., Elias, M., Caselli, E., Prati, F., Salverda, M.L.M., de Visser, J.A.G.M., Fraser, J.S. & Tawfik, D.S., Negative epistasis and evolvability in TEM-1 β -lactamase – The thin line between an enzyme's conformational freedom and disorder, *Journal of Molecular Biology* (2015), doi: [10.1016/j.jmb.2015.05.011](https://doi.org/10.1016/j.jmb.2015.05.011)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Negative epistasis and evolvability in TEM-1 β -lactamase – The thin line between an enzyme's conformational freedom and disorder

Eynat Dellus-Gur¹, Mikael Elias^{1*†}, Emilia Caselli², Fabio Prati², Merijn L.M. Salverda³, J. Arjan G.M. de Visser⁴, James S. Fraser^{5*} and Dan S. Tawfik^{1*}

¹Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel.

²Department of Chemistry, University of Modena, Modena, Italy.

³Institute for Translational Vaccinology (Intravacc), Bilthoven, The Netherlands

⁴Laboratory of Genetics, Department of Plant Sciences, Wageningen University, P.O.Box 309, 6700 AH Wageningen, the Netherlands.

⁵Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, USA.

*Corresponding authors: Dan S. Tawfik, E-mail: dan.tawfik@weizmann.ac.il; Mikael Elias, E-mail: Mikael.Elias@gmx.fr; James S. Fraser, E-mail: James.Fraser@ucsf.edu.

† Present address: University of Minnesota, Department of Biochemistry, Molecular Biology and Biophysics & Biotechnology Institute, St. Paul, MN 55108, USA

Keywords: protein evolution, enzyme evolution, protein disorder, protein folds, Conformational diversity, Interactions network.

Abstract

Epistasis is a key factor in evolution, since it determines which combinations of mutations provide adaptive solutions and which mutational pathways towards these solutions are accessible by natural selection. There is growing evidence for the pervasiveness of sign epistasis – a complete reversion of mutational effects, particularly in protein evolution, yet its molecular basis remains poorly understood. We describe the structural basis of sign epistasis between G238S and R164S, two adaptive mutations in the antibiotic-resistance enzyme TEM-1 β -lactamase. Separated by 10Å, these mutations initiate two separate trajectories towards increased hydrolysis rates and resistance towards second and third-cephalosporins antibiotics. Both mutations allow the enzyme's active-site to adopt alternative conformations and accommodate the new antibiotics. By solving the corresponding set of crystal structures we found that whereas G238S induces discrete conformations, R164S causes local disorder. When combined, the mutations in 238 and 164 induce local disorder whereby nonproductive conformations that perturb the enzyme's catalytic pre-organization dominate. Specifically, Asn170 that coordinates the deacylating water molecule is misaligned, in both the free and the inhibitor-bound double mutant. This local disorder is not restored by stabilizing, global suppressor mutations and thus leads to an evolutionary cul-de-sac. Conformational dynamism therefore underlines the reshaping potential of proteins structures and functions, but also limits protein evolvability because of the fragility of the interactions networks that maintain protein structures.

Epistasis, i.e., non-additive effects of mutations, determines the topography of fitness landscapes^{1;2}. Hence, epistasis describes which combinations of mutations provide adaptive solutions, and which stepwise mutational pathways leading to these solutions are selectively accessible^{3,4,5; 6}. In doing so, epistasis determines the capacity of organisms, and of their proteins, to evolve and adapt, i.e., their evolvability. Interestingly, by increasing the dependence of mutational pathways on early mutations, epistasis causes mutational pathways to be historically contingent upon initial mutations^{7; 8}. This influence is particularly strong in case of sign epistasis, where the sign of the fitness effect of a mutation (beneficial or deleterious) depends on its genetic background³. For example, mutations with individual beneficial effects, but combined deleterious effect, show reciprocal sign epistasis. They create a rugged adaptive landscape, where different trajectories may lead to adaptive peaks of different heights^{1; 3; 4; 9; 10; 11}, and whereby some of the trajectories can turn into evolutionary dead ends, or *cul-de-sacs*^{12; 13; 14}.

Epistasis, including sign epistasis, is pervasive^{2; 3}. The phenomenon itself is measured and relates to organismal fitness. It is clear, however, that its origins lie in antagonistic interactions between mutations, either in separate genes (or proteins) or within the same gene/protein. However, the molecular basis of epistasis remains poorly understood¹⁰. We have better understanding of positive epistasis at the single gene level, such as in deer-mouse hemoglobin adapted to high altitude¹⁵. Typically, stabilizing mutations, which have no effect on protein fitness on their own, are revealed as beneficial when they compensate for new-function mutations that are typically destabilizing¹⁶. Such stabilizing mutations can have local, specific compensatory effects^{17; 18}, or global effects, when they can compensate for a whole range of destabilizing mutations¹⁶ in non-contacting residues^{19; 20; 21}. One case study of positive epistasis in the vertebrate glucocorticoid receptor revealed a mutation that was initially neutral, yet by

reorienting an alpha helix, enabled the acceptance of an adaptive mutation that would be deleterious on its own²². Overall, it appears that stabilization of the protein's configuration promotes its adaptive potential and underlines positive epistasis^{21; 22}. However, a detailed, structural understanding of negative sign epistasis is lacking: Why do certain combinations of mutations, each of which is beneficial individually, become deleterious when combined^{23; 24}?

Here, we explored a case of negative reciprocal sign epistasis between two adaptive mutations in TEM-1 β -lactamase, an enzyme present in numerous antibiotics resistant bacteria. These studied mutations, G238S and R164S, are amongst the most common mutations in clinically isolated variants, and therefore represent a highly relevant case study^{25; 26}. Wild-type TEM-1 confers resistance to natural penicillin antibiotics. However, in the clinic, strains with new resistance mutations are frequently isolated. This increased resistance is the outcome of adaptive evolution of TEM-1 for new, so-called 2nd and 3rd cephalosporins antibiotics. Adaptive evolution of TEM-1 has occurred in numerous parallel events and can be readily reproduced in the laboratory²⁵. The increased catalytic activity of TEM-1 to 2nd and 3rd cephalosporins antibiotics therefore comprises a broadly accepted model for enzyme evolution^{3; 25; 26}. Owing to the large sampling of TEM-1 sequences by natural and directed evolution, the absence of certain combinations of mutations likely indicates their negative epistatic interaction. This is the case with G238S and R164S, which were individually found in 91 and 51 different variants, respectively, both in laboratory and clinical contexts²⁵. However, their combination has only been observed in one clinical sample²⁷. Indeed, the combination of G238S and R164S results in *in vivo* resistance levels to cefotaxime that are lower than each of the single mutants (4-fold lower than R164S, and 8-fold lower than G238S) and are similar to wild-type TEM-1 (ref. 7; 27). Laboratory experiments attempting to evolve variants carrying the R164S mutation toward

high cefotaxime activity indicated that R164S blocks the path to maximal cefotaxime degradation activity⁷. As detailed in the Results section, one mutation, E104K, improves R164S's activity, but the activity of the R164S/E104K double mutant was still inferior to G238S/E104K²⁴. The only traceable trajectory to higher cefotaxime resistance in these laboratory evolution experiments was through reversion of R164S and take-over by G238S (ref. 7). Thus, R164S seems to comprise an evolutionary *cul-de-sac*⁷. However, the molecular basis underlining the limited adaptive potential of R164S and of the reciprocal sign epistasis with G238S remain unclear.

The strong, non-additive interaction between R164S and G238S is surprising for two reasons: firstly, the mutation sites are not in direct contact ($>10\text{\AA}$ apart), and secondly, combining these mutations does not further compromise TEM-1's global configurational stability^{7; 16}. To determine the structural basis for this classical case of reciprocal sign epistasis, and to understand why R164S might lead to an evolutionary *cul-de-sac*, we solved the crystal structures of the R164S, G238S and double mutants R164S/G238S, in their free forms and bound to an inhibitor. Although these mutations are key first-step mutations in the adaptation of TEM-1 to 2nd and 3rd cephalosporins antibiotics, the structure of enzymes harboring these mutations with no additional active-site mutations have not been available thus far. The combination of free vs. inhibitor bound and of variable temperature X-ray data allowed for increased sampling of the conformational ensemble of TEM-1, thus unraveling the structural basis of negative epistasis and evolvability in TEM-1.

Results

Mutations that confer TEM-1 with the ability to hydrolyze new antibiotics are located mostly on the loops surrounding the active site: the ‘ Ω -loop’ (residues 164-179 (ref. 28)), the ‘238-loop’ (residues 238-242 (ref. 29)) and the ‘101-loop’ (residues 101-111 (ref. 30)). The mutations studied here, G238S and R164S, enhance cefotaxime hydrolysis (3rd cephalosporins antibiotic) and reside on the 238-loop and the Ω -loop, respectively^{7; 29}. Mutation G238S increases cefotaxime resistance levels by ~16-fold: the MIC, the minimal inhibitory concentration, increases from 0.06 μ g/ml to 1 μ g/ml (**Table 1**). Mutation R164S increases cefotaxime resistance by only ~8-fold^{7; 31} (MIC = 0.5 μ g/ml), but exhibits increased resistance levels with other, primarily 2nd-generation antibiotics^{31; 32}, as well as a weaker tradeoff than G238S with ampicillin resistance (**Table 1** (ref. 7)). In the absence of epistasis, the combined effect of the R164S and G238S mutations is expected to be multiplicative at the level of MIC (or additive at the level of log MIC³³), thus resulting in up to ~120-fold higher cefotaxime resistance levels relative to wild-type. However, the double mutant’s MIC is only increased ~2-fold relative to wild type (**Table 1**). Accordingly, the catalytic efficiency (k_{cat}/K_M) of the R164S/G238S mutant with cefotaxime is essentially identical to that of the single mutant R164S, and about 20-fold lower than that of G238S (**Table 1** (ref. 7)). These losses in catalytic efficiency, combined with a more minor effect on TEM-1’s conformational stability⁷, result in the *in vivo* MIC levels of the R164S/G238S mutant being lower than each of the single mutants (**Table 1** (see also Ref. 7)). In addition, the R164S/G238S mutant exhibits a very low k_{cat} value with ampicillin, the original substrate, and accordingly, much reduced MIC levels. The K_M of the double mutant with ampicillin was improved. However, given the covalent intermediate mechanism of TEM-1, this change may in fact relate to a drastic slowdown in the rate of deacylation, and not improved substrate affinity³⁴. Further, in both the wild-type and the mutants, the K_M is much lower than the applied antibiotic

concentrations, and therefore the improvement in K_M has little effect on resistance levels. Thus, R164S and G238S exhibit negative reciprocal epistasis: the expected positive effect of both individual mutations is inverted to negative when they are combined.

Crystal structures. Due to their compromised configurational stability, the single mutants, let alone the double mutant, were poorly expressed in *E. coli*³¹. Their tendency to crystallize was also poor, especially of the R164S/G238S double mutant. Indeed, although a whole range of TEM-1 mutant structures is available, a structure of this double mutant has not been thus far attainable, not even at the background of a stabilizing mutation, M182T, that is routinely observed in clinical variants. We therefore made use of a stabilized variant of TEM-1 dubbed v13, that carries 7 stabilizing mutations located on the surface and away from the active-site, including mutations that are commonly observed in clinical variants such as M182T (for a list of mutations, and their structural locations, see **supplementary Fig. 1**). This variant is essentially identical in structure to wild-type TEM-1 (ref. 16), and the kinetic parameters of the studied 164 and 238 mutants in the background of v13 are essentially identical to the same mutations in the wild-type background (**Table 1**). Further, structures of v13 show the same active-site loop configurations, and the same levels of loop mobility as wild-type TEM-1 (ref. 16). The individual effects of G238S and R164S, and the non-additive effects of combining them, on the k_{cat}/K_M values for both cefotaxime and ampicillin are essentially identical to the effects of these mutations at the wild-type's background (**Table 1**). The *in vivo* effects could not be measured because the hyper-stability of v13 has major effects on periplasmic export. However, the inconsistencies in the MIC level are the outcome of differences in expression levels and export rates, and are therefore irrelevant to issues under study here. The comparison of the *in vitro* measured kinetic parameters and structures of the wild-type background (Table 1; Ref. 16)

indicate that v13 comprises a valid model for studying the structural and mechanistic origins of the loss of TEM-1's catalytic function when G238S and R164S are combined as manifested in k_{cat}/K_M values, and especially in k_{cat} (discussed below).

Overall, we solved 10 different structures of stabilized variant carrying the studied active-site mutations, individually and in combination (R164S/G238S) at both cryogenic and room temperatures. We obtained structures of the free enzyme form, and structures bound to EC25 (ref. 35), a covalent borate-based inhibitor that mimics the deacylation tetrahedral intermediate Π^{36} (**supplementary Fig. 2**). EC25's structure resembles ampicillin and not cefotaxime. However, a suitable boronate mimic of cefotaxime is not available (the one available, LP08, only mimics the thiazolyl part but not the lactam ring and its bulky substituents³⁵). However, in the double mutant, cefotaxime and ampicillin show the very same trend of loss of activity relative to the single G238S mutant, both in relation to MIC values *in vivo* and to the *in vitro* kinetic parameters (**Table 1**). Additionally, as shown below, the origins of negative epistasis are in the disturbance of TEM-1's catalytic machinery, and the mechanism of catalysis is essentially identical for both cefotaxime and ampicillin³⁷.

Structures were solved by molecular replacement and refined to 1.05-2.4Å resolutions. The anisotropic B-factors were refined in the high resolution data as detailed in **supplementary Table 1**. All of the newly solved structures align well to one another and to the published wild-type TEM-1 structure (PDB code: 1ZG4 (ref. 38)). The only significant conformational differences between the structures are in the loops surrounding the active-site, foremost in the Ω -loop where R164S resides and in the 238-loop that includes G238S. Analyzing the main loop conformations in each of these structures reveals that the G238S mutation samples between two well-defined discrete 238-loop conformations, but that R164S results in a diverse Ω -loop

conformational ensemble (**Fig. 1**). It should be noted that the crystal packing of the TEM-1 structures obtained here involves the omega-loop where R164S resides. Nonetheless, all structures presented in this study exhibit the same space group C2, although the published wild-type TEM-1 structure relates to a different one (P2₁2₁2, (ref. 38). The comparison of the single to the double mutant is therefore based on all structures belonging to the same space group. Additionally, packing interactions tend to be stabilizing and thus to favor a single conformation. Hence, if anything, our data underestimates the conformational ensembles of the mutants, and specifically of the double mutant.

The effects of G238S. In v13-G238S mutant, the dominant conformation of the 238-loop is perturbed, while the Ω -loop conformation more closely resembles the wild-type conformation (**Fig. 2**). Inspection of the 238-loop Fourier difference density maps of both the free and EC25-bound structures revealed alternative loop conformations that resemble a wild-type-like conformation (**Fig. 2 and Fig. 3 G238S – middle top and bottom**; density for the loop is fit by the dominant “major” conformation shown in thick sticks and a secondary “minor” conformation shown as thin sticks). The alternative, open conformation, presumably allows access to the much larger cefotaxime substrate, and thereby increases the k_{cat}/K_M of G238S by ≥ 130 -fold relative to wild-type, in which, the closed conformation prevails. However, the perturbed, open conformation also results in the loss of a key interaction between the Ω -loop and 238-loop (E240’s backbone amide with N170’s backbone carbonyl oxygen– **Fig. 2 and Fig. 3** shown as red dashed-circle). Apart from connecting the two loops, the interaction with E240 seems to be critical for stabilizing N170, a key catalytic residue that coordinates the de-acylating water molecule³⁹. Concordantly, there is electron density consistent with a second N170 side chain conformation in a non-catalytic orientation. However, unlike v13-R164S, in the v13-G238S

structure, the main chain conformation of N170 closely resembles the catalytically competent wild-type conformation (**Fig. 2**). Upon ligand binding, the minor conformation of the 238-loop shifts to restore the interaction between the loops (**Fig. 3 G238S - middle bottom**: the red-dashed circle encompasses the wild-type and minor 238-loop conformations). **Supplementary Movie 2** illustrates the relatively small changes in the Ω -loop's configuration upon inhibitor binding in comparison to the R164 mutant.

The incomplete shift of the minor conformation to the catalytically competent conformation suggests that formation of the transition state(s) leading to and/or from the acyl-enzyme intermediate involves a higher entropic penalty for G238S than for wild-type. As shown below, this cost seems far more pronounced in the R164S mutant that samples between many perturbed Ω -loop conformations in the free enzyme.

The effects of R164S. As previously reported^{28; 40; 41}, the R164S mutant increased the conformational freedom of the Ω -loop, as indicated by high B-factors and a weak electron density (**Table 2, supplementary Fig. 4 and 5**) relative to other parts of the protein. Indeed, the increased conformational freedom of the Ω -loop was suggested to increase TEM-1's active-site accessibility for larger substrates such as cefotaxime^{25; 31}. The other active-site loops, including the 238-loop, are well ordered in the R164S free and inhibitor-bound v13 structures (**Fig. 2**). The dominant conformation of the Ω -loop is distinct from the wild-type conformation (C-alpha RMSD is $\sim 2\text{\AA}$; **Fig. 2**). Accordingly, the interaction between E240-NH and N170-O is lost (**Fig. 3** shown as the red dashes). Indeed, in the inhibitor-free structure, N170 exhibits an outward rotation relative to the wild-type conformation, away from the deacylating water (**Fig. 2**). The deacylating water is accordingly shifted, although its other ligating residue, E166, exhibits wild-type conformation. Upon EC25 binding, the mobility of the Ω -loop is reduced, the critical

interaction with the 238-loop is restored, and N170, as well as E166, adopt wild-type conformation (**Table 2** and **Fig. 2**). **Supplementary Movie 1** illustrates the changes in the Ω -loop's configuration upon inhibitor binding, the concomitant gain of interaction between the Ω -loop and 238-loop and the relocation of N170.

The binding of EC25 to TEM-1 is covalent (**supplementary Fig. 2**), thereby promoting its ability to shift the equilibrium towards the well-organized conformation of the Ω -loop and N170. The cost of N170's alternative, non-catalytic conformation in the case of the actual substrate is therefore likely to be much higher. These results suggest that substrate binding to the R164S mutant involves an increased entropic penalty due to the poor preorganization of the Ω -loop, as indicated by N170's perturbed conformation, and the elevated B-factors for the entire Ω -loop (a detailed analysis is provided below). However, the perturbed Ω -loop conformational dynamics of the free enzyme are likely required to accommodate larger 2nd and 3rd cephalosporins antibiotics.

The observed differences in loop configurations, and particularly of the Ω -loop, may relate to crystal packing, and may thus, fail to report the enzyme's actual configuration(s) in solution. Note, however, that all v13 structures presented here belong to the same space group (**Supplementary Table 2**). Additionally, the Ω -loop's configuration does not seem to vary differently between structures belonging to different space groups, suggesting that crystal packing does not significantly alter this loop's configuration (**Supplementary Figure 3**).

The combined effect of R164S and G238S. A systematic analysis of the v13 double mutant's structure did not reveal potential effects of the mutations on substrate binding. Indeed, neither R164S nor G238S are in direct contact with the substrate (as far as can be judged from the EC25 complex) and neither takes part in catalysis. Therefore, we examined the structures for longer-

range effects. Both single mutants exhibit conformational changes within the active-site loops that are necessary for accommodating the larger cefotaxime substrate^{29; 41}. However, these two mutations have different side-effects on the active-site conformational ensemble, suggesting that the mechanism underlining TEM-1's adaptation towards cefotaxime is more complex than previously proposed^{42; 43}. In the v13 R164S/G238S double mutant, a wider ensemble of conformations is seen that includes nonproductive conformations in both the free and inhibitor-bound states (**Fig. 2**). Specifically, like in the v13-R164S mutant, the Ω -loop of the double mutant is conformationally heterogeneous. Additionally, like in the v13-G238S mutant, the perturbed conformation of the 238-loop dominates, and the near-wild-type conformation is scarcely populated (**Fig. 2 and Fig. 3 R164S/G238 – right top**: the major and minor conformations of the 238-loop are shown as thin sticks with the position of E240-N indicated by spheres in both minor and major conformations). However, in the double mutant the 238-loop and Ω -loop fail to establish interactions that stabilize the catalytically competent conformation of N170. Further, N170's side-chain carbonyl oxygen takes the place of the deacylating water that is not present in the double mutant's free structure, although E166 exhibits a wild-type-like conformation. Even covalent inhibitor binding is insufficient to drive the rearrangement. **Supplementary Movies 3 and 4** address the minor and major 238-loop conformations, respectively. The morph movies illustrate the profound changes in the Ω -loop's configuration upon inhibitor binding, the loss of interaction between the Ω -loop and 238-loop in both the free and inhibitor bound structures, and the displacement of N170.

The loss of the catalytically competent N170 conformation relates to a new, nonproductive interaction seen exclusively in the double mutant: in the bound structure E171's side chain interacts with the backbone amide of E240 within the perturbed conformation of the

238-loop (**Fig. 2 and Fig. 3 R164S/G238 – right top**: The interaction between E171 and E240 is indicated by red dashes). The non-productive 171-240 interaction originates to the loss of E171's side-chain interaction with R164 upon mutating this residue to Ser. However, the 171-240 interaction does not occur in the v13-R164S single mutant, simply because the perturbed 238-loop conformation is only populated when G238 is mutated to Ser. Therefore, negative epistasis between these two mutations has two primary structural causes: 1) Excessive conformational flexibility when the two mutations are combined decreases the pre-organization of the enzyme active site in the free state; 2) a non-native 171-240 interaction between the omega and 238 loops seems to shift the equilibrium against the productive active-site conformation. As discussed in detail below, the shift towards nonproductive conformations is also apparent in the double mutant's free structure, where the deacylating water molecule is missing and, further, N170's side-chain and the catalytic S70's hydroxyl are within contacting distance. This interaction is likely to severely hamper the active-site (**Fig. 2**).

The disturbance of active site pre-organization. Enzyme active-sites, including TEM-1's, are pre-organized in a catalytically optimal conformation^{44; 45}. However, the high mobility of the Ω -loop, in both the v13 single R164S mutant and especially in the v13-R164S/G238S double mutant, induced alternative, suboptimal configurations (**Fig. 4A**). To determine the magnitude of conformational change the apo-enzyme exhibit in order to get to the catalytically optimal conformation, we examined the differences between the free and the inhibitor-bound enzyme structures. Specifically, we observed the displacement of N170, a residue that coordinates the deacylating water molecule³⁹. In wild-type and G238S, the overall deviations in the active-site's structure upon binding are minimal ($\text{RMSD} \leq 0.39 \text{ \AA}$ **Table 3**) and thus N170 is largely pre-aligned for catalysis. In v13-R164S and R164S/G238S, however, N170 is misaligned in the free

structures, and the Ω -loop exhibits a large conformational change upon inhibitor binding (RMSD \approx 1.85Å; **Table 3 Fig. 4**). This displacement dominates the conformational ensembles of the v13-R164S mutant and the v13 double mutant R164S/G238S, but is only a minor conformation in the v13-G238S mutant (**Figure 4A and Table 4**). Consistent with this structural analysis, the R164S mutation was shown to impair de-acylation in class-A β -lactamases^{40; 41}. Thus, the prevailing conformation(s) in the free enzyme states of v13-R164S and v13-R164S/G238S probably exhibit no, or poor catalytic activity. The entropic cost of selecting from multiple conformations, combined with the impaired configuration of N170 even in the inhibitor bound structure, are manifested in the very low k_{cat} value of the double mutant. As expected, inhibitor binding shifts the equilibrium toward the catalytic conformation in all mutants (**Fig. 4B, Table 4**). However, even in the inhibitor-bound v13-R164S/G238S structure, a wild-type-like configuration of N170 is only observed at 0.5 occupancy alongside an alternative, highly perturbed conformation that is unlikely to be catalytically active (**Fig. 4B, in green; Table 4**).

B-factors analysis. To further test the idea that increased conformational flexibility underlies the sign negative epistasis between R164S and G238S, we examined the refined crystallographic temperature factors (B-factors) along TEM-1's polypeptide chain. B-factors model how much an atom deviates from its average position in the crystal^{46; 47}. However, this model includes both dynamic and static disorder and is sensitive to model errors. B-factors are especially useful reporters of molecular flexibility when discrete conformations cannot be distinguished in the electron density. Since alternative conformations for the 238-loop are apparent at low electron density levels (**supplementary Fig. 4 and 5**), we carefully modeled these fragments and then normalized the B-factors within each structure to indicate the relative mobility of atoms⁴⁷. The normalized B-factors indicate that in the free structures of the mutants, both the omega and G238

loops exhibit higher flexibility in the mutants than in wild-type TEM-1. Interestingly, while R164S mutation induces only local changes in the flexibility of the Ω -loop, the G238S mutation induces alternative conformations of the 238-loop and increased B-factors in both the 238 and the Ω -loop. In the double mutant, we observed that both of the loops exhibit increased B-factors. However, the Ω -loop exhibits normalized B-factors that are almost 2-fold higher than in each of the single mutants (**Table 2**). To determine how flexibility changes upon inhibitor binding, we analyzed the patterns of B-factors in the inhibitor-bound structures. In both of the single mutants, inhibitor binding reduced the B-factor values. However, in the double mutant, the reduction in the loop's B-factors upon binding is much lower than in any of the single mutants (**Table 2**). The B-factor analysis therefore supports the hypothesis that the double mutant exhibits a higher degree of conformational freedom compared to the single mutants. Hence, we suggest that both the negative epistasis between R164S and G238S mutant, and the decreased evolvability of alleles carrying R164S, result from the mutations widening the conformational ensembles to a level that penetrates into the active-site and hampers catalysis.

Discussion

Sign epistasis modulates the fitness landscape such that traversing from one peak (i.e., a given sequence and function) to another may occur via only few trajectories^{3,48; 49}. Understanding the underlying causes of this particular form of epistasis may make evolutionary processes, and enzyme design and engineering, easier to understand and predict². Here, we revealed the basis of reciprocal sign epistasis between two mutations in TEM-1 β -lactamase that initiate alternative resistance pathways to second and third- cephalosporins antibiotics including cephalosporins. As nearly all other new-function mutations in enzymes, R164S and G238S occur not in the catalytic

residues, and not even in residues that directly contact the substrate⁵⁰. Rather, they are located in loops that surround the active-site, and in residues that are >10Å apart. Nonetheless, these mutations strongly interact phenotypically at the level of enzyme function. Individually, each of the studied adaptive mutations introduces conformational changes in the active site loops that enable TEM-1's active-site to better accommodate a new larger substrate. However, the level of conformational diversity introduced by these mutations, and the side effects of widening the enzyme's conformational ensemble, differ between these two mutations. While one mutation, G238S, introduces new well-defined conformations, the other, R164S, introduces disorder along large segments of the Ω -loop (**Fig. 1**). Further, in the G238S mutant, the 238-loop conformation dominates in both the free and inhibitor-bound enzyme forms – hence, this mutation simply reshapes the loop (**Table 3**). In contrast, R164S induces an ensemble of different conformations, most of which are of nearly equal stability and are hence rarely represented (manifested in the weak electron density of the Ω -loop in the crystal). Binding of the inhibitor, and accordingly, substrate binding and formation of the transition state, shift the equilibrium towards the catalytically active conformation (**Table 3**).

The existence of multiple non-active conformations is manifested in the k_{cat} value of the R164S/G238S double mutant with ampicillin (TEM-1's preferred substrate) being ~10-fold lower than that of R164S, and 260-fold lower than that of wild-type (**Table 1**). Assuming 'conformational-selection', *i.e.*, multiple pre-existing conformations and substrate binding shifting the equilibrium towards the functional conformation, the measured k_{cat} relates to the k_{cat} of individual conformers multiplied by their relative representation. Thus, a loss of ~100-fold in k_{cat} upon combining R164S and G238S (relative to the expected additive effect) suggests that the fraction of the catalytically optimal conformer(s) dropped to ~1%. The role of multiple pre-

existing conformers in mediating the multi-functionality of proteins^{51; 52} and their evolutionary potential⁵³ is widely recognized. But the evolutionary cost of excessive conformational freedom, as observed here, is generally overlooked. One case highlighting the cost of increased conformational freedom relates to a laboratory engineered trypsin/chymotrypsin loop swap⁵⁴. This swap resulted in an enzyme that was not only catalytically impaired but also lacked the expected chymotrypsin-like specificity. The low turnover rate and specificity related to the high mobility of active-site loops, and their stabilization via a single point mutation led to the recovery of the enzyme's rate and specificity. In triosephosphate isomerase⁵⁵, mutations destabilizing the loops surrounding the active-site, severely hamper catalytic activity, and especially the k_{cat} , as observed here. Similarly, in RnaseH⁵⁶, insertion/deletion of a glycine altered the ensemble of loop conformers and modulated the catalytic rate. Here we addressed the effects of mutations that occurred along adaptive evolutionary trajectories. We found that both G238S and R164S increase the representation of a new active-site conformation that better accommodates cefotaxime. However, combining these two mutations results in non-catalytic conformers dominating the conformational ensemble, and in non-native interactions between the loops such as the hydrogen bond between E171 and E240 (**Fig. 2**; R164S/G238S red dashes).

Thus, in TEM-1, sign epistasis between mutations that increase enzyme function seems to be the outcome of 'conformational anarchy' whereby the catalytically optimal conformation becomes diluted to a degree that severely hampers catalytic efficiency. Previous work described the role of compensatory mutations with global stabilizing effects in the evolution of new enzyme functions, and specifically in TEM-1^{19; 31; 50}. However, as far as the catalytic parameters are concerned, the negative epistasis effect between R164S and G238S in TEM-1 is not alleviated by global, stabilizing, compensatory mutations – not by M182T (ref.7; 24; 31), TEM-

1's most frequently observed stabilizing mutation, and not even in v13 that carries 7 stabilizing mutations including another known global suppressor, L201A (ref. 57). The inability to evolve a more stable and rigid core and scaffold to compensate for increased mobility of the active-site loops relates to the polarized architecture of TEM-1 (ref. 16).

Our results therefore reveal a delicate balance between the adaptive benefit associated with increased structural freedom and its cost. An example of this tradeoff is antibody affinity maturation. Germ-line antibodies exhibit high conformational plasticity yet low affinity, which is compensated by the higher avidity of IgM antibodies. Maturation involves the funneling of conformations towards the one that binds the antigen, and hence increase affinity^{58 59}.

Why do these TEM-1 mutations behave so differently – R164S leading to a local adaptive peak *versus* G238S leading towards higher fitness? Both R164 and G238 are part of an elaborate network that shapes TEM-1's active-site (**Fig. 2**). However, whereas R164 has 7 contacts with neighboring residues, G238 has only two. Contacts density correlates with how buried a residue is⁶⁰, yet R164 and G238 exhibit the same relative solvent accessibility. Thus, R164 exhibits higher than average contact density for its degree of burial (mean = 4.8 contacts per residue) whereas G238 is far below average (supplementary **Fig. 6**). This difference goes beyond the expected for the different sizes of these amino acids. The high connectivity of R164 results in the collapse of this interaction network upon mutating to serine (**Fig. 2**) and underlines the appearance of non-catalytic conformations (**Fig. 4**). Negative epistasis in TEM-1 may therefore relate to the network properties of protein folds. These so-called 'small-world' networks^{61; 62} are characterized by most residues (nodes) being connected via few hubs. In such networks, highly connected residues as R164 are relatively rare, and their perturbation severely undermines the network⁶². These networks, however, are highly robust to changes in weakly

connected nodes as G238. Accordingly, position 238 shows ~10-fold faster evolutionary rate than 164 (238 evolves 3 time slower than the protein's average, and R164 30-fold slower as calculated by rate4site⁶³). Owing to its limited connectivity within the active-site's interactions network, position 238 exhibits high robustness as well as innovability – the potential to promote new enzymatic functions⁶⁴.

Overall, our analysis suggests a tight link between protein structural networks, conformational ensembles and evolvability. At least for the case of TEM-1 beta-lactamase, we observed a delicate balance between the potential of mutations to introduce new conformations that may initiate new functions, and their cost in over-broadening the protein's conformational ensemble. The latter appears to result in negative epistasis and what seems to be an evolutionary *cul-de-sacs* in TEM-1's adaptation via the R164S mutation. Better understanding of how a protein's architecture, structural networks and conformational dynamics at different time scales affect this balance will promote our understanding of protein evolution and also advance the design and engineering of new proteins^{65; 66}.

Materials and Methods

Crystallization. Wild-type TEM-1 and mutants were expressed and purified as previously described¹⁶. For crystallization, concentrated solutions of TEM-1 variants (60 mg/ml) in 25 mM Tris pH 8.4 and 100 mM NaCl were submitted to crystallization trials. Crystallization was performed using the hanging-drop vapor diffusion method. Equal volumes (0.5 μ l) of protein and reservoir solutions were mixed, and the resulting drops were equilibrated at 293 K against a 400 μ l reservoir solution made of 9% (wt/vol) polyethylene glycol (PEG) 8000, 100 mM MES pH 6.2, and 200mM Ca(OAc)₂ for all mutants; and 6% PEG 8000, 100 mM MES buffer pH 6.2, 200mM Ca(OAc)₂ and 50 μ M NaF for the wild-type. Microseeding was performed to obtain larger crystals. For the structures bound to EC25 (ref. 35), the crystals were soaked for 1 hour at 293 K in a solution containing 50mM EC25, 20% (wt/vol) PEG 8000, 25% PEG 600, 100 mM MES pH 6.5, and 200mM Ca(OAc)₂ for all mutants. The wild-type TEM1 crystals were soaked using the same protocol in a solution containing 50mM EC25, 25% PEG 600, 100 mM MES pH 6.5, and 200mM Ca(OAc)₂.

Data collection at 100 K. Crystals of ligand-free proteins were mounted on microloops (MiTeGen, USA) and transferred into a cryo-protectant solution containing 20% PEG 8000, 25% PEG 600, 100 mM MES pH 6.5, and 200mM Ca(OAc)₂ for 1 min, and then flash-cooled in liquid nitrogen. For the bound wild-type and v13 structures, the soaking solution was used as cryo-protectant. X-ray diffraction data of mutant G238S free and in complex with EC25, R164S and R164S/G238S in complex with EC25 were collected on a Rigaku R-Axis IV++ imaging plate area detector mounted on a Rigaku RU-H3R generator with CuK α radiation focused by Osmic confocal mirrors (in-house source). The X-ray diffraction data of the wild-type crystals in complex with EC25, of v13 mutants R164S and R164S/G238S (free forms) were collected at

ID29 beam-line (European Synchrotron Facility (ESRF), Grenoble, France) using a PILATUS 6M detector. The diffraction data of R164S crystals were collected on ID14-1 beam-line (ESRF) using an ADSC Q210 detector.

Data collection at 293 K. Crystals were mounted on microloops (MiTeGen) and transferred into capillaries (Hampton, UK). Diffraction data were collected on a Rigaku R-Axis IV++ imaging plate area detector mounted on our in-house source.

Data processing and refinement. Diffraction data were integrated and scaled using *XDS* package⁶⁷. Molecular replacement was performed using *MOLREP*⁶⁸ using the structure of wild-type TEM-1 (PDB: 1ZG4 (ref. 38)) as the starting model. Manual model improvement was performed using *Coot*⁶⁹ and the refinement was performed using *REFMAC5* (ref. 68) and *PHENIX*⁷⁰. Data collection and refinement statistics are provided in supplementary Table 1. Figures depicting structures were prepared with PyMOL.

Relative loops B-factors. The occupancies of all residues in all analyzed structures were set at a value of 1 (for residues with alternative conformations, the sums of occupancies were set at 1). The structures were re-refined using *REFMAC5* (ref. 68). The relative loops B-factor values were obtained by normalizing the B-factor values of the loops main chain atoms by the average B-factor of main chain atoms of the whole structure as described in¹⁶.

RMSD between free and bound structures. RMSD calculations were done using the Swiss-PDB viewer, using main chain atoms of the loops or the entire structures.

Evolutionary rates. Evolutionary rates were calculated using *rate4site*⁶³ as described in¹⁸. This method computes the relative evolutionary rate for individual protein positions across the entire phylogeny, via Bayesian Estimation. The rates are normalized with respect to the phylogeny such that the expected rate over all sites is 1. Hence, the rate of each site indicates how rapidly

the site evolves relative to the mean. The sequence alignment was taken from ConSurf, and contained 150 sequences with 95%-35% identity to wild-type TEM-1.

Number of contacts and ASA values were calculated as in Ref. ¹⁶.

ACCEPTED MANUSCRIPT

Accession codes

Protein Data Bank: Atomic coordinates and structure factors have been deposited with the accession codes PDB ID: 4OPY, 4OPQ, 4OP5, 4OQI, 4OQH, 4OQO, 4OQG, 4OP8, 4OPR, 4OPZ.

Acknowledgments

Financial support by the Israel Science foundation, and EMBO visiting fellowship and NIH (OD009180) to JSF, are gratefully acknowledged. DST is the Nella and Leon Benozio Professor. We thank Linda Shimon for invaluable assistance with the home source and room temperature X-ray data collections.

References

1. Breen, M. S., Kemena, C., Vlasov, P. K., Notredame, C. & Kondrashov, F. A. Epistasis as the primary factor in molecular evolution. *Nature* **490**, 535-8.
2. de Visser, J. A. & Krug, J. (2014). Empirical fitness landscapes and the predictability of evolution. *Nat Rev Genet* **15**, 480-90.
3. Weinreich, D. M., Delaney, N. F., Depristo, M. A. & Hartl, D. L. (2006). Darwinian evolution can follow only very few mutational paths to fitter proteins. *Science* **312**, 111-4.
4. Bridgham, J. T., Ortlund, E. A. & Thornton, J. W. (2009). An epistatic ratchet constrains the direction of glucocorticoid receptor evolution. *Nature* **461**, 515-9.
5. Borman, A. M., Paulous, S. & Clavel, F. (1996). Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. *J Gen Virol* **77** (Pt 3), 419-26.
6. Maisnier-Patin, S., Berg, O. G., Liljas, L. & Andersson, D. I. (2002). Compensatory adaptation to the deleterious effect of antibiotic resistance in *Salmonella typhimurium*. *Mol Microbiol* **46**, 355-66.
7. Salverda, M. L., Dellus, E., Gorter, F. A., Debets, A. J., van der Oost, J., Hoekstra, R. F., Tawfik, D. S. & de Visser, J. A. (2011). Initial mutations direct alternative pathways of protein evolution. *PLoS Genet* **7**, e1001321.
8. Blount, Z. D., Borland, C. Z. & Lenski, R. E. (2008). Historical contingency and the evolution of a key innovation in an experimental population of *Escherichia coli*. *Proc Natl Acad Sci U S A* **105**, 7899-906.
9. Poelwijk, F. J., Kiviet, D. J., Weinreich, D. M. & Tans, S. J. (2007). Empirical fitness landscapes reveal accessible evolutionary paths. *Nature* **445**, 383-6.
10. de Visser, J. A., Cooper, T. F. & Elena, S. F. (2011). The causes of epistasis. *Proc Biol Sci* **278**, 3617-24.
11. Poelwijk, F. J., Tanase-Nicola, S., Kiviet, D. J. & Tans, S. J. (2011). Reciprocal sign epistasis is a necessary condition for multi-peaked fitness landscapes. *J Theor Biol* **272**, 141-4.
12. Burch, C. L. & Chao, L. (2000). Evolvability of an RNA virus is determined by its mutational neighbourhood. *Nature* **406**, 625-8.
13. Rozen, D. E., Habets, M. G., Handel, A. & de Visser, J. A. (2008). Heterogeneous adaptive trajectories of small populations on complex fitness landscapes. *PLoS One* **3**, e1715.
14. Woods, R. J., Barrick, J. E., Cooper, T. F., Shrestha, U., Kauth, M. R. & Lenski, R. E. (2011). Second-order selection for evolvability in a large *Escherichia coli* population. *Science* **331**, 1433-6.
15. Natarajan, C., Inoguchi, N., Weber, R. E., Fago, A., Moriyama, H. & Storz, J. F. (2013). Epistasis among adaptive mutations in deer mouse hemoglobin. *Science* **340**, 1324-7.
16. Dellus-Gur, E., Toth-Petroczy, A., Elias, M. & Tawfik, D. S. (2013). What makes a protein fold amenable to functional innovation? Fold polarity and stability trade-offs. *J Mol Biol* **425**, 2609-21.
17. Toth-Petroczy, A. & Tawfik, D. S. (2013). Protein insertions and deletions enabled by neutral roaming in sequence space. *Mol Biol Evol* **30**, 761-71.

18. Toth-Petroczy, A. & Tawfik, D. S. (2011). Slow protein evolutionary rates are dictated by surface-core association. *Proc Natl Acad Sci U S A* **108**, 11151-6.
19. Lunzer, M., Golding, G. B. & Dean, A. M. (2010). Pervasive cryptic epistasis in molecular evolution. *PLoS Genet* **6**, e1001162.
20. Bloom, J. D., Silberg, J. J., Wilke, C. O., Drummond, D. A., Adami, C. & Arnold, F. H. (2005). Thermodynamic prediction of protein neutrality. *Proc Natl Acad Sci U S A* **102**, 606-11.
21. Bloom, J. D., Labthavikul, S. T., Otey, C. R. & Arnold, F. H. (2006). Protein stability promotes evolvability. *Proc Natl Acad Sci U S A* **103**, 5869-74.
22. Ortlund, E. A., Bridgham, J. T., Redinbo, M. R. & Thornton, J. W. (2007). Crystal structure of an ancient protein: evolution by conformational epistasis. *Science* **317**, 1544-8.
23. Martin, G., Elena, S. F. & Lenormand, T. (2007). Distributions of epistasis in microbes fit predictions from a fitness landscape model. *Nat Genet* **39**, 555-60.
24. Schenk, M. F., Szendro, I. G., Salverda, M. L., Krug, J. & de Visser, J. A. (2013). Patterns of Epistasis between beneficial mutations in an antibiotic resistance gene. *Mol Biol Evol* **30**, 1779-87.
25. Salverda, M. L., De Visser, J. A. & Barlow, M. (2010). Natural evolution of TEM-1 beta-lactamase: experimental reconstruction and clinical relevance. *FEMS Microbiol Rev* **34**, 1015-36.
26. Guthrie, V. B., Allen, J., Camps, M. & Karchin, R. (2011). Network models of TEM beta-lactamase mutations coevolving under antibiotic selection show modular structure and anticipate evolutionary trajectories. *PLoS Comput Biol* **7**, e1002184.
27. Giakkoupi, P., Tzelepi, E., Tassios, P. T., Legakis, N. J. & Tzouveleakis, L. S. (2000). Detrimental effect of the combination of R164S with G238S in TEM-1 beta-lactamase on the extended-spectrum activity conferred by each single mutation. *J Antimicrob Chemother* **45**, 101-4.
28. Petrosino, J. F. & Palzkill, T. (1996). Systematic mutagenesis of the active site omega loop of TEM-1 beta-lactamase. *J Bacteriol* **178**, 1821-8.
29. Cantu, C., 3rd & Palzkill, T. (1998). The role of residue 238 of TEM-1 beta-lactamase in the hydrolysis of extended-spectrum antibiotics. *J Biol Chem* **273**, 26603-9.
30. Petit, A., Maveyraud, L., Lenfant, F., Samama, J. P., Labia, R. & Masson, J. M. (1995). Multiple substitutions at position 104 of beta-lactamase TEM-1: assessing the role of this residue in substrate specificity. *Biochem J* **305** (Pt 1), 33-40.
31. Wang, X., Minasov, G. & Shoichet, B. K. (2002). Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. *J Mol Biol* **320**, 85-95.
32. Stapleton, P. D., Shannon, K. P. & French, G. L. (1999). Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors. *Antimicrob Agents Chemother* **43**, 1881-7.
33. Mani, R., St Onge, R. P., Hartman, J. L. t., Giaever, G. & Roth, F. P. (2008). Defining genetic interaction. *Proc Natl Acad Sci U S A* **105**, 3461-6.
34. Fersht, A. (1977). *Enzyme Structure and Mechanism*, W. H. Freeman.
35. Drawz, S. M., Taracila, M., Caselli, E., Prati, F. & Bonomo, R. A. (2011). Exploring sequence requirements for C(3)/C(4) carboxylate recognition in the Pseudomonas

- aeruginosa cephalosporinase: Insights into plasticity of the AmpC beta-lactamase. *Protein Sci* **20**, 941-58.
36. Strynadka, N. C., Martin, R., Jensen, S. E., Gold, M. & Jones, J. B. (1996). Structure-based design of a potent transition state analogue for TEM-1 beta-lactamase. *Nat Struct Biol* **3**, 688-95.
37. Fabre, H., Eddine, N. H. & Berge, G. (1984). Degradation kinetics in aqueous solution of cefotaxime sodium, a third-generation cephalosporin. *J Pharm Sci* **73**, 611-8.
38. Stec, B., Holtz, K. M., Wojciechowski, C. L. & Kantrowitz, E. R. (2005). Structure of the wild-type TEM-1 beta-lactamase at 1.55 Å and the mutant enzyme Ser70Ala at 2.1 Å suggest the mode of noncovalent catalysis for the mutant enzyme. *Acta Crystallogr D Biol Crystallogr* **61**, 1072-9.
39. Brown, N. G., Shanker, S., Prasad, B. V. & Palzkill, T. (2009). Structural and biochemical evidence that a TEM-1 beta-lactamase N170G active site mutant acts via substrate-assisted catalysis. *J Biol Chem* **284**, 33703-12.
40. Levitt, P. S., Papp-Wallace, K. M., Taracila, M. A., Hujer, A. M., Winkler, M. L., Smith, K. M., Xu, Y., Harris, M. E. & Bonomo, R. A. (2012). Exploring the role of a conserved class A residue in the Omega-Loop of KPC-2 beta-lactamase: a mechanism for ceftazidime hydrolysis. *J Biol Chem* **287**, 31783-93.
41. Vakulenko, S. B., Taibi-Tronche, P., Toth, M., Massova, I., Lerner, S. A. & Mobashery, S. (1999). Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEM(pUC19) beta-lactamase from Escherichia coli. *J Biol Chem* **274**, 23052-60.
42. Orenica, M. C., Yoon, J. S., Ness, J. E., Stemmer, W. P. & Stevens, R. C. (2001). Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. *Nat Struct Biol* **8**, 238-42.
43. Shimamura, T., Ibuka, A., Fushinobu, S., Wakagi, T., Ishiguro, M., Ishii, Y. & Matsuzawa, H. (2002). Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin. *J Biol Chem* **277**, 46601-8.
44. Strynadka, N. C., Adachi, H., Jensen, S. E., Johns, K., Sielecki, A., Betzel, C., Sutoh, K. & James, M. N. (1992). Molecular structure of the acyl-enzyme intermediate in beta-lactam hydrolysis at 1.7 Å resolution. *Nature* **359**, 700-5.
45. Warshel, A. (1998). Electrostatic origin of the catalytic power of enzymes and the role of preorganized active sites. *J Biol Chem* **273**, 27035-8.
46. Parthasarathy, S. & Murthy, M. R. (1997). Analysis of temperature factor distribution in high-resolution protein structures. *Protein Sci* **6**, 2561-7.
47. Yuan, Z., Bailey, T. L. & Teasdale, R. D. (2005). Prediction of protein B-factor profiles. *Proteins* **58**, 905-12.
48. Weinreich, D. M., Watson, R. A. & Chao, L. (2005). Perspective: Sign epistasis and genetic constraint on evolutionary trajectories. *Evolution* **59**, 1165-74.
49. Povolotskaya, I. S. & Kondrashov, F. A. (2010). Sequence space and the ongoing expansion of the protein universe. *Nature* **465**, 922-6.
50. Tokuriki, N., Stricher, F., Serrano, L. & Tawfik, D. S. (2008). How protein stability and new functions trade off. *PLoS Comput Biol* **4**, e1000002.
51. Phillips, A. H., Zhang, Y., Cunningham, C. N., Zhou, L., Forrest, W. F., Liu, P. S., Steffek, M., Lee, J., Tam, C., Helgason, E., Murray, J. M., Kirkpatrick, D. S., Fairbrother,

- W. J. & Corn, J. E. (2013). Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling. *Proc Natl Acad Sci U S A* **110**, 11379-84.
52. Weng, J. K., Philippe, R. N. & Noel, J. P. (2012). The rise of chemodiversity in plants. *Science* **336**, 1667-70.
53. Tokuriki, N. & Tawfik, D. S. (2009). Protein dynamism and evolvability. *Science* **324**, 203-7.
54. Hedstrom, L., Perona, J. J. & Rutter, W. J. (1994). Converting trypsin to chymotrypsin: residue 172 is a substrate specificity determinant. *Biochemistry* **33**, 8757-63.
55. Sampson, N. S. & Knowles, J. R. (1992). Segmental movement: definition of the structural requirements for loop closure in catalysis by triosephosphate isomerase. *Biochemistry* **31**, 8482-7.
56. Butterwick, J. A. & Palmer, A. G., 3rd. (2006). An inserted Gly residue fine tunes dynamics between mesophilic and thermophilic ribonucleases H. *Protein Sci* **15**, 2697-707.
57. Marciano, D. C., Pennington, J. M., Wang, X., Wang, J., Chen, Y., Thomas, V. L., Shoichet, B. K. & Palzkill, T. (2008). Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 beta-lactamase. *J Mol Biol* **384**, 151-64.
58. James, L. C. & Tawfik, D. S. (2003). Conformational diversity and protein evolution--a 60-year-old hypothesis revisited. *Trends Biochem Sci* **28**, 361-8.
59. Foote, J. & Milstein, C. (1994). Conformational isomerism and the diversity of antibodies. *Proc Natl Acad Sci U S A* **91**, 10370-4.
60. Richards, F. M. (1974). The interpretation of protein structures: total volume, group volume distributions and packing density. *J Mol Biol* **82**, 1-14.
61. Bode, C., Kovacs, I. A., Szalay, M. S., Palotai, R., Korcsmaros, T. & Csermely, P. (2007). Network analysis of protein dynamics. *FEBS Lett* **581**, 2776-82.
62. Greene, L. H. & Higman, V. A. (2003). Uncovering network systems within protein structures. *J Mol Biol* **334**, 781-91.
63. Mayrose, I., Graur, D., Ben-Tal, N. & Pupko, T. (2004). Comparison of site-specific rate-inference methods for protein sequences: empirical Bayesian methods are superior. *Mol Biol Evol* **21**, 1781-91.
64. Payne, J. L. & Wagner, A. (2014). The robustness and evolvability of transcription factor binding sites. *Science* **343**, 875-7.
65. Gobeil, S. M., Clouthier, C. M., Park, J., Gagne, D., Berghuis, A. M., Doucet, N. & Pelletier, J. N. (2014). Maintenance of Native-like Protein Dynamics May Not Be Required for Engineering Functional Proteins. *Chem Biol* **21**, 1330-40.
66. Tokuriki, N. & Jackson, C. J. (2014). Enzyme dynamics and engineering: one step at a time. *Chem Biol* **21**, 1259-60.
67. Kabsch, W. (1993). Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. *Journal of Applied Crystallography* **26**, 795-800.
68. (1994). The CCP4 suite: programs for protein crystallography. *Acta Crystallogr D Biol Crystallogr* **50**, 760-3.
69. Emsley, P. & Cowtan, K. (2004). Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* **60**, 2126-32.
70. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J.,

- Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C. & Zwart, P. H. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213-21.
71. Neves, M. A., Yeager, M. & Abagyan, R. (2012). Unusual arginine formations in protein function and assembly: rings, strings, and stacks. *J Phys Chem B* **116**, 7006-13.

Table 1. Kinetic and stability parameters, and *E. coli* resistance levels of the TEM-1 variants.

^a v13 is a stabilized variant of TEM-1 described in Ref. 16 that exhibits essentially the same enzymatic parameters as the wild-type TEM-1.

n.d. – not detectable. A linear dependency of initial rates on substrate concentrations was observed (while applying the highest substrate concentrations possible within maximal absorbance of $OD^{264nm} \leq 1.5$), and thus only k_{cat}/K_M could be determined.

n.m. – not measured. The increased stability may affect the export rates and yields of TEM-1 to the periplasm, and thus the MIC values of stabilized variants were not measured.

Amp - ampicilline; Ctx - cefotaxime.

Table 2. The Ω - and 238-loops B-factors^a

^a B-factors indicate the level of thermally-induced mobility of the loops' backbone atoms.

^b Calculated for the set of the structures obtained at cryo temperature (**supplementary Table 1**). Noted are the average B-factors for backbone atoms of all loop residues, normalized to the average B-factor for all backbone atoms in a given structure.

^c All structures here are on the background of stabilized v13 and belong to the same space group, thus minimizing biases due to crystal packing, particularly in the Ω -loop.

Table 3. Structural deviations between the free and inhibitor-bound structures.

Noted are average RMSD values for main-chain atoms (in Å)

Table 4. The key interactions underlining TEM-1's catalysis.

The figure below depicts a superposition of the key active site residues in free (gray, PDB:1ZG4 (ref. 38)) and bound (green, PDB: 4OQG) wild-type structures. The distances for the indicated bonds are provided in the table below.

n.d. – Not detected: the interaction is not observed because at least one of the interacting TEM-1 side-chain atoms is disordered.

n.a. – not applicable. These contacts are not hydrogen bonds.

^a N170 appears in two alternative conformations in this structure.

^b The oxyanion hole water or the borate oxygen atom mimicking it.

^c The de-acylating water or the borate oxygen atom mimicking it.

^d Table 4's figure: TEM-1's active-site configuration

Fig. 1- Superposition of active-site loops in all structures. (A) Superposition of the main Ω -loop conformation in all wild-type structures (gray) and in the different v13-R164S mutant structures (blue). Room-temperature structures are in green; note that in the double-mutant (R164S/G238S) room temperature structure, the Ω -loop could not be modeled and is therefore missing. Shown in sticks are the side-chains of N170 that aligns the de-acylating water (W1; gray for wild-type, red for mutants) and the catalytic S70 for reference. (B) Superposition of the main 238-loops conformation in all v13 structures containing the G238S mutation (blue), in wild-type (gray). The mutants structures determined at room temperature are in green. Shown is A237 whose backbone amide positions the oxyanion-hole water (W2). The loop conformations shown relate to the main clearly observed in the electron density of individual structures. Structures included are: **A** 4OPY, 4OPQ, 4OP5, 4OQI, 4OQH, 4OQ0, 4OQG, 1ZG4; **B** 4OPQ, 4OP8, 4OP4, 4OQI, 4OPZ, 4OQ0, 4OQG, 1ZG4 (ref. 38) (**supplementary Table 1**).

Fig. 2 - The Ω -loop and 238-loop interactions network. A snapshot of the Ω -loop, the 238-loop, and the key catalytic residues in the free structures (left column) and in structures with the inhibitor EC25 bound (right column). Shown are wild-type TEM-1 (gray), the single v13 mutants R164S (yellow) and G238S (blue), and the double v13 mutant R164S/G238S (green). Catalytic residues are in smoked pink and EC25 is in light pink ball-sticks. Minor conformations of the loops are shown in light blue. Dashed lines represent putative interactions involving R164 and G238, and interactions lost in the R164S/G238S double mutant are marked in blue in the wild-type. The non-native interaction in the double mutant between E171 and S238 is in red. A putative stacking interaction between R164 and R178 (ref. 71) is also marked.

Fig. 3 – Electron density maps of the 238 and Ω -loops. The wild-type structure is shown for comparison in partially transparent magenta. The 2mFo-DFc electron density maps for the two v13 single mutants, and the v13 double mutant, are contoured at 0.5 (cyan) and 1 (blue) sigma, and mFo-DFc electron density maps are contoured at +3.0 (green) and -3.0 (red) sigma. (The m and D terms indicate that the maps were calculated while correcting for down-weight poorly phased reflections, and including a scaling factor to account for overall scattering differences due to missing components such as partially ordered waters).

Fig. 4 – The mutations impair TEM-1's catalytic pre-organization. Superposition of the key active-sites residues in wild-type (gray), the v13 single G238S (blue) and R164S (yellow) mutants, and the v13 double mutant R164S/G238S (green). (A) Ligand-free structures. (B) The EC25 inhibitor complexes (EC25 is shown in ball-sticks). In the free structures, W1 represents the de-acylating water and W2 in the oxyanion-hole water⁴⁴. In the EC25-bound structures, the borate's oxygen atoms, marked as O1 and O2, sit in the locations of W1 and W2, respectively. Note the dual conformation of N170 in the EC25 complex of R164S/G238S.

Figure 1




Figure 2




Figure 3




Figure 4




Table 1

<i>Variant</i>	<i>Antibiotic</i>	K_M (μM)	k_{cat} (sec^{-1})	k_{cat}/K_M ($M^{-1}sec^{-1}$)	<i>MIC</i> ($\mu g/ml$)
<i>Wild-type</i>	<i>Amp</i>	71 \pm 9	1857 \pm 27	26 \pm 1.3 $\times 10^6$	4096
	<i>Ctx</i>	<i>n.d.</i>	<i>n.d.</i>	0.1 $\times 10^4 \pm 6$	0.06
<i>Stabilized v13^a</i>	<i>Amp</i>	63 \pm 13	1040 \pm 21	16.5 \pm 1.3 $\times 10^6$	<i>n.m.</i>
	<i>Ctx</i>	<i>n.d.</i>	<i>n.d.</i>	0.07 $\times 10^4 \pm 10$	
<i>Wild-type + G238S</i>	<i>Amp</i>	26 \pm 4	42 \pm 0.4	1.4 \pm 0.08 $\times 10^6$	1024
	<i>Ctx</i>	403 \pm 146	50 \pm 3	13 \pm 4 $\times 10^4$	1
<i>Stabilized v13+ G238S</i>	<i>Amp</i>	18 \pm 5	72 \pm 0.5	4 \pm 0.36 $\times 10^6$	<i>n.m.</i>
	<i>Ctx</i>	502 \pm 65	75 \pm 1.4	14.5 \pm 1 $\times 10^4$	
<i>Wild-type+ R164S</i>	<i>Amp</i>	37 \pm 7	75 \pm 25	2.0 \pm 0.8 $\times 10^6$	4096
	<i>Ctx</i>	536 \pm 51	2.5 \pm 0.1	4.7 \pm 0.4 $\times 10^3$	0.5
<i>Stabilized v13+ R164S</i>	<i>Amp</i>	140 \pm 36	164 \pm 24	1.1 \pm 0.7 $\times 10^6$	<i>n.m.</i>
	<i>Ctx</i>	887 \pm 173	5 \pm 0.5	5.3 \pm 2.5 $\times 10^3$	
<i>Wild-type + G238S+R164S</i>	<i>Amp</i>	11 \pm 11	7 \pm 3	0.9 \pm 0.5 $\times 10^6$	512
	<i>Ctx</i>	578 \pm 26	2.6 \pm 0.1	4.5 \pm 0.5 $\times 10^3$	0.125
<i>Stabilized v13 +G238S+R164S</i>	<i>Amp</i>	6 \pm 0.85	11 \pm 0.2	1.8 \pm 0.4 $\times 10^6$	<i>n.m.</i>
	<i>Ctx</i>	1300 \pm 137	12.5 \pm 0.85	9.6 \pm 2 $\times 10^3$	

Table 2


Structure^c	Relative loops B-factors (Å²)^b	
	Free enzyme	EC25 complex
Wild-type 238-loop	0.98	-
Wild-type omega-loop	1.24	-
G238S 238-loop	1.18	1.06
G238S omega-loop	2.56	1.75
R164S 238-loop	1.02	1.12
R164S omega-loop	2.54	2.22
R164S/G238S 238-loop	1.46	1.24
R164S/G238S omega-loop	4.75	3.34

Table 3


Structure	All residues (H25-W286)	Ω-loop (E164-R179)	238-loop (S238-S242)
wild-type	0.37	0.18	0.22
G238S	0.34	0.39	0.20
R164S	0.39	1.83	0.07
R164S/ G238S	0.33	1.86	0.12

Table 4

Interaction #	Interaction distances (Å)								
	1	2	3	4	5	6	7	8	9
Free enzyme									
Wild-type	2.5	2.8	2.8	2.4	3.2	2.9	2.8	3.0	2.7
R164S	2.7	3.5	3.2	2.9	2.9	3.1	2.7	2.9	2.7
G238S	2.5	2.3^a 6.1	2.9	2.8	2.4	3.0	2.7	2.9	2.8
R164S/G238S	n.d.	n.d.	n.d.	2.9	2.9	3.1	2.7	2.8	2.7
EC25-bound									
Wild-type	2.8	2.9	2.2	2.6	3.8	3.1	2.9	2.5	3.1
R164S	2.5	2.6	2.6	2.5	2.8	2.8	2.8	2.8	2.6
G238S	2.5	2.7	2.5	2.5	2.8	2.8	2.7	2.8	2.8
R164S/G238S	2.5	2.7^a 6.1	2.4	2.4	3.0	2.8	2.7	2.8	2.7
Acceptor	E166 O ϵ	N170 O δ	n.a.	n.a.	W2/ O2 ^b	W2/ O2 ^b	K73 N ζ H ₃	S130 O γ	N13 2 O δ
Donor	W1/ O1 ^c	W1/ O1 ^c	n.a.	n.a.	A237 N α	S70 N α	S70 O γ	K73 N ζ H ₃	K73 N ζ H ₃



Graphical abstract



Highlights

- **Epistasis – non-additive effects of mutations, dictate evolutionary trajectories**
- **When combined, two adaptive TEM-1 β -lactamase mutations result in loss of function**
- **Individually, these mutations introduce new conformations accepting new substrates**
- **When combined, these mutations cause local disorder and disrupt the active-site**
- **Conformational dynamism promotes protein evolvability but restricts mutational options**